- Alexion (ALXN) voluntarily recalls some vials of Soliris due to the presence of "visible particles."
- According to company estimates, the recall and subsequent replacement of the vials affects ~1-2% of monthly vial consumption.
- The supply of Soliris to patients won't be interrupted based on currently available information and ALXN says there have been "no identifiable safety concerns" attributed to the affected single lot. (8-K)
- BofA has apparently spoken with management: The EMA agrees with the company's decision to recall the affected vials.
- ALXN -1.3% premarket.
From other sites
at CNBC.com (Jan 8, 2015)
at CNBC.com (Jan 7, 2015)
at CNBC.com (Nov 14, 2014)
at CNBC.com (Oct 1, 2014)
at CNBC.com (Aug 14, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs